Drug intelligence / Profile preview

PTx800

Development stage: Unknown
Administration: Oral

Overview

PTx800 is an orally administered, rapid-dissolving lozenge developed as a daily oral care product aiming to improve gum health in older adults with mild to moderate gingivitis. Its mechanism of action, active ingredient(s), and detailed formulation are not specified in available trial documentation, but it is assessed for feasibility, efficacy on gingival status, and reduction of oral pathogen burden over 6 weeks. The product is designed as a cost-effective, nontoxic, and easy-to-use supplement to oral hygiene specifically for older adults at risk for poor oral health[4].

Beyond the preview

Go deeper on PTx800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTx800.

Explore the full profile